Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilotumumab in persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer
NCT01039207Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- Oct 2010
- Primary completion
- Jul 2012
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of rilotumumab in ovarian carcinoma, fallopian tube carcinoma (PFTC), primary peritoneal carcinoma (PPC), sponsored by GOG Foundation. Started Oct 2010; status: completed.
02
Drugs
rilotumumab
03
Conditions
ovarian carcinomafallopian tube carcinoma (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT01039207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01039207.